Alligator Bioscience announces that Shanghai Henlius Biotech has dosed the first American patient in a global phase III study with HLX22 in combination with trastuzumab and chemotherapy for HER2-positive metastatic gastric cancer. HLX22 is an anti-HER2 monoclonal antibody developed by Henlius under license from AbCloneAlligator is entitled to 35 percent of AbClon's revenue from the agreement with Henlius in the event of future approval.
|
Published July 14, 2025
Alligator comments on Henlius' phase III study
Notes
Sofinnova Partners raises EUR 650 million in new fund
Merck acquires Cidara for approximately USD 9,2 billion
Coegin Pharma launches first Follicopeptide product
Ascelia Pharma receives FDA acceptance for Orviglance application
Diamyd Medical passes safety review ahead of Phase III readout
Egetis reports positive results from the ReTRIACt study
Mikael Dolsten withdraws his nomination to Novo's board
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account